In this study cohort, we observed that after induction therapy, the CR rates in childhood AML that harbored the FLT3/ITD mutation were inferior to patients with FLT3/ITD wild-type, which indicated that mutant FLT3/ITD patients had a poor early treatment response. Here, FLT3 is linked to acute myeloid leukemia.